Purple Biotech Ltd (PPBT): Forecast Levels Chart

Symbol and logo of brand Purple Biotech Ltd (PPBT)

Purple Biotech (PPBT) is implementing AI and powerful robotics to digitalize targeted drug development, eliminating routine tasks for scientists. Automation of cell-model testing accelerates therapy discovery with a small staff, and the indicator stands at 17.03. The company independently promotes its own molecules, limiting itself only to manufacturing contracts. The asset's market dynamics are presented below, reflecting the business's current market quotes.

Kitov Pharma - PPBT Consensus Target (period 07/04/2022 - 11/11/2026)
Original product of Purple Biotech Corp

The virtualized antibody production model of Purple Biotech (PPBT) makes the business valuation dependent on external contracts; therefore, changes in the consensus valuation of the stock reflect market confidence in the effectiveness of such partnerships. This indicator synthesizes an average price target from investment bank reports, filtering out short-term order book noise to identify the long-term asset revaluation trend, although excessive data smoothing may delay the reaction to institutional exits.

Competing companies

ONC: Forecast Levels Chart|Price Target Chart Halozyme HALO|RVMD (Revolution Medicines Inc) - Forecast Levels Chart|Ascentage - Analyst Consensus Forecast|CGON: Price Target Chart|URGN (UroGen Pharma Ltd.) - Consensus Target|BCAX: Analyst Forecast Prices|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast Y-mAbs Corp (YMAB)|Price Target Chart Aura Biosciences, Inc. AURA|CADL: Broker Consensus Forecast|Accuray - Analyst Consensus Forecast|SELLAS Life Sciences (SLS) - Consensus Target|ACTU: Analyst Consensus Forecast|Average Forecast Price Citius Oncology Inc (CTOR)|Price Target Chart TuHURA Biosciences Inc.|TARA: Fair Value Consensus|Consensus Target FATE (Fate Therapeutics)|WHWK (aadibio.com) - Fair Value Consensus|Analyst Consensus Forecast TCRX (TScan Therapeutics, Inc.)|CSBR - Consensus Target|XBIT: Consensus Target|CVM - Analyst Consensus Forecast|OS Therapies (OSTX) - Price Target Chart|Radiopharm Theranostics Ltd - Fair Value Consensus|ARTV (Artiva Biotherapeutics Inc.) - Analyst Consensus Forecast|Average Forecast Price Adlai Nortye Limited ANL|Price Target Chart Veru Inc. (VERU)|TPST: Forecast Levels Chart|Xilio Therapeutics - Consensus Target|Analyst Consensus Forecast Renovaro Biosciences RENB|MURA - Price Target Chart|Fair Value Consensus KAPA (Kairos Pharma Ltd)|onkuretherapeutics.com (OKUR) - Price Target Chart|Forecast Levels Chart GDTC (CytoMed Therapeutics Limited)|Price Target Chart Curis Inc.|Price Target Chart APLM|Analyst Consensus Forecast THAR|ADVB - Average Forecast Price|Genprex, Inc. - Consensus Target|Fair Value Consensus CLDI|Sunshine Biopharma - Analyst Consensus Forecast|XBIO: Price Target Chart|SLRX: Analyst Consensus Forecast|AONC - Analyst Median Target|Price Target Chart BeiGene, Ltd.|Average Forecast Price checkpointtx.com CKPT|Consensus Target ELEV (Elevation Oncology, Inc.)|Analyst Forecast Prices ICAD|Analyst Consensus Forecast IKNA (Ikena Oncology)|Notable Labs Corp (NTBL) - Average Forecast Price|Viracta - Analyst Consensus Forecast|morphosys.com (MOR) - Consensus Target|NAYA: Analyst Consensus Forecast|Ascentage Pharma Group International - Fair Value Consensus